ClinicalTrials.gg
TerminatedNCT06772415Updated Nov 17, 2026

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of GenSci122 tablet 50mg and GenSci122 tablet 250mg in Advanced Solid Tumor, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Terminated at 9 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Why this study was terminated
The sponsor adjusted its research and development strategy
Updated Nov 17, 2026Now TerminatedStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
163
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a first-in-human (FIH), multicenter, open-label, phase I study to evaluate the safety, tolerability, PK and preliminary efficacy of GenSci122 in participants with advanced solid tumors. The study consists of 2 parts: Part 1- dose-escalation and Part 2- dose expansion. The primary endpoint of Dose escalation is To assess the safety and tolerability of GenSci122. The primary endpoint of Dose expansion is to evaluate the preliminary anti-tumor activity of GenSci122 in participants with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide and sign the informed consent form (ICF).
  2. Male or female participants ≥18 years old at the time of consent.
  3. Meeting the requirements of tumor types shown below:

    Dose escalation:

    Participants with a histological or cytological diagnosis of recurrent or advanced solid tumors who have failed or are intolerant to standard treatment, or have no standard therapy.

    Dose expansion:

    Participants with a histological or cytological diagnosis of recurrent or metastatic advanced solid tumors who have failed or are intolerant to standard treatment, or have no standard therapy.

  4. Participants agree to provide fresh or archived tumor tissue as well as corresponding pathological report.
  5. Survival expectations are ≥ 12 weeks.
  6. performance status (ECOG PS) 0 to 1 (Appendix 1).
  7. At least one measurable target lesion
  8. Participants with adequate organ function at the time of screening (requiring no blood transfusion, no use of hematopoietic stimulating factor or human albumin or use of drug for correction within 14 days before the first dose)
  9. All toxicity related to prior cancer therapies must have resolved to ≤ Grade 1
  10. Congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the time of occurrence and must have resolved completely.
  11. Normal on screening evaluation
  12. Participants with a known infection are eligible if the following criteria are met:

    a. Stable on antiretroviral therapy for ≥ 4 weeks before the first dose of GenSci122.

    d. Viral load of \< 400 copies per mL at screening. e. ≥ 350 cells/μL at screening.

  13. virus (HBV) and virus (HCV) test is negative. If participants have active HBV infection: HBV- deoxyribonucleic acid (DNA) must be \< 500 IU/mL (or must be \< 2500 copy/mL if copy/mL is the only unit available in the study site) and are willing to receive antiviral therapy throughout the study (treatment in accordance with local standard of care, e.g., entecavir); participants with positive HCV ribonucleic acid (RNA) must receive antiviral therapy in accordance with the local standard treatment guideline and have ≤ 5.0 Grade 1 elevated hepatic function.
  14. Women of (WOCBP) must have a serum pregnancy test negative within 7 days before the first dose of GenSci122. WOCBP must agree to avoid pregnancy during the study and agree to the use 2 effective methods (hormonal or barrier method of birth control, or abstinence) before study entry, for the duration of study participation, and in the following 6 months after discontinuation of Gensci122
  15. Men with a partner(s) of childbearing potential must take appropriate precautions to avoid fathering a child from screening until 3 months after discontinuation of GenSci122 and to use appropriate barrier contraception or abstinence

Exclusion criteria

Exclusion Criteria:

  1. agent or anticancer therapy within 5 half-lives or 4 weeks (whichever is shorter) before the first dose of GenSci122. In addition, no concurrent investigational anti-cancer therapy is permitted.
  2. Major surgery (excluding placement of vascular access) within 4 weeks before the first dose of GenSci122.
  3. Radiotherapy within 4 weeks before the first dose of GenSci122. Or participants have not yet recovered from acute effects of radiotherapy to baseline before the first dose of GenSci122.
  4. Symptomatic primary central nervous system (CNS) tumor, , , or untreated spinal cord compression.
  5. active cardiovascular disease or history of myocardial infarction within 6 months before the first dose of GenSci122.
  6. Active uncontrolled systemic bacterial, viral, or fungal infection, or serious ongoing intercurrent illness, such as hypertension or diabetes, despite optimal treatment. Screening for chronic conditions is not required.
  7. Inability to swallow pills or clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of GenSci122.
  8. Pregnancy or lactation.
  9. History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma, for which by the date of the first dose of GenSci122, at least 3 years of complete remission and no other treatment is needed or expected during the study period.
  10. Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse
  11. Allergic to GenSci122 tablet or its components.
  12. Any serious illness, uncontrolled inter-current illness, psychiatric illness, or other medical history, including lab results, which in the opinion of investigator or medical monitor would be likely to impact safety or compliance with study requirements or confounds the ability to interpret the data.
  13. Has a treatment history of KIF18A inhibitor.
  14. Participants with DNA polymerase epsilon (POLE) gene hotspot mutated, or hypermutator phenotype.
  15. Other conditions that are not eligible for inclusion based on the investigator's judgment.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    Single arm

    Drug: GenSci122 tablet 50mg · Drug: GenSci122 tablet 250mg

Interventions

  • DrugGenSci122 tablet 50mg

    Orally Once Daily

  • DrugGenSci122 tablet 250mg

    Orally Once Daily

06

What researchers measure

Primary outcomes

  1. Dose escalation: Incidence of dose-limiting toxicities (DLTs).

    Time frame: 2 years

  2. Dose expansion: Objective response rate (ORR) evaluated by investigator based on response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).

    Time frame: 3 Years

Secondary outcomes

  1. Incidence and severity of TEAEs.

    Time frame: 3 years

  2. Maximum Plasma Concentration (Cmax) of Gensci122

    Time frame: 3 years

  3. Time to Maximum Plasma Concentration (Tmax) of Gensci122

    Time frame: 3 years

  4. Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval for Gensci122

    Time frame: 3 years

  5. Duration of Response (DOR)

    Time frame: 3 years

  6. Progression-free Survival (PFS)

    Time frame: 3 years

  7. Overall Survival (OS)

    Time frame: 3 years

07

Study locations

9 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2025 to primary completion in Oct 2026, 21 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Dec 2028 → Oct 2026 and completion Mar 2031 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 13, 2025
StartActual
Jan 2, 2025
Primary completionActual
Oct 22, 2026was Dec 2028
CompletionActual
Oct 22, 2026was Mar 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated The sponsor adjusted its research and development strategy
changed Nov 17, 2026
Sites
9 sites added, 9 sites removed
Show 9 added (9 China)
  • Beijing Cancer Hospital · Beijing, China
  • Cancer Hospital Chinese Academy of Medical Sciences · Beijing, China
  • Henan Cancer Hospital · Zhengzhou, China
  • The first affiliated hospital of Zhengzhou university · Zhengzhou, China
  • Hunan Cancer Hospital · Changsha, China
  • Nanjing Medical University First Affiliated Hospital · Nanjing, China
  • Cancer Hospital of Shandong First Medical University · Jinan, China
  • ZhongShan Hospital Fudan University · Shanghai, China
  • Tianjin Medical University Cancer Institute & Hospital · Tianjin, China
Show 9 removed
  • Cancer Hospital Chinese Academy of Medical Sciences · Beijing, China
  • Beijing Cancer Hospital · Beijing, China
  • Henan Cancer Hospital · Zhengzhou, China
  • The first affiliated hospital of Zhengzhou university · Zhengzhou, China
  • Hunan Cancer Hospital · Changsha, China
  • Jiang Su Province Hospital · Nanjing, China
  • Cancer Hospital of Shandong First Medical University · Jinan, China
  • ZhongShan Hospital Fudan University · Shanghai, China
  • Tianjin Medical University Cancer Institute & Hospital · Tianjin, China
Nov 17, 2026
Start date
Jan 8, 2025→Jan 2, 2025
Nov 17, 2026
Primary completion
Dec 2028→Oct 22, 2026 (actual)
Nov 17, 2026
Study completion
Mar 2031→Oct 22, 2026 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Recruiting→Terminated
    Why stopped The sponsor adjusted its research and development strategy
    9 sites added, 9 sites removed
    Show 9 added (9 China)
    • Beijing Cancer Hospital · Beijing, China
    • Cancer Hospital Chinese Academy of Medical Sciences · Beijing, China
    • Henan Cancer Hospital · Zhengzhou, China
    • The first affiliated hospital of Zhengzhou university · Zhengzhou, China
    • Hunan Cancer Hospital · Changsha, China
    • Nanjing Medical University First Affiliated Hospital · Nanjing, China
    • Cancer Hospital of Shandong First Medical University · Jinan, China
    • ZhongShan Hospital Fudan University · Shanghai, China
    • Tianjin Medical University Cancer Institute & Hospital · Tianjin, China
    Show 9 removed
    • Cancer Hospital Chinese Academy of Medical Sciences · Beijing, China
    • Beijing Cancer Hospital · Beijing, China
    • Henan Cancer Hospital · Zhengzhou, China
    • The first affiliated hospital of Zhengzhou university · Zhengzhou, China
    • Hunan Cancer Hospital · Changsha, China
    • Jiang Su Province Hospital · Nanjing, China
    • Cancer Hospital of Shandong First Medical University · Jinan, China
    • ZhongShan Hospital Fudan University · Shanghai, China
    • Tianjin Medical University Cancer Institute & Hospital · Tianjin, China
    Start date Jan 8, 2025→Jan 2, 2025
    Primary completion Dec 2028→Oct 22, 2026 (now actual)
    Study completion Mar 2031→Oct 22, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06772415
Responsible party
Sponsor
First posted
Jan 13, 2025
Start date
Jan 2, 2025
Primary completion
Oct 22, 2026
Completion
Oct 22, 2026
Last update
Nov 17, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion